Vallabhaneni, Snigdha

Candida Bloodstream Infections Among Persons Who Inject Drugs — Denver Metropolitan Area, Colorado, 2017–2018

Barter, D. M., Johnston, H. L., Williams, S. R., Tsay, S. V., Vallabhaneni, S., & Bamberg, W. M. (2019) · MMWR. Morbidity and Mortality Weekly Report

Antifungal resistance and susceptibilityInfective Endocarditis Diagnosis and Management

Cited by 22

Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018.

Gold, J. A. W., Seagle, E. E., Nadle, J., Barter, D. M., Czaja, C. A., Johnston, H., Farley, M. M., Thomas, S., Harrison, L. H., Fischer, J., et al. (2021) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 20

Injection Drug Use-Associated Candidemia: Incidence, Clinical Features, and Outcomes, East Tennessee, 2014–2018

Rossow, J. A., Gharpure, R., Brennan, J., Relan, P., Williams, S. R., Vallabhaneni, S., Jackson, B. R., Graber, C. R., Hillis, S. R., Schaffner, W., et al. (2020) · The Journal of Infectious Diseases

Antifungal resistance and susceptibilityInfective Endocarditis Diagnosis and Management

Cited by 17

Antifungal susceptibility testing practices at acute care hospitals enrolled in the National Healthcare Safety Network, United States, 2011–2015.

Vallabhaneni, S., Sapiano, M., Weiner, L. M., Lockhart, S. R., & Magill, S. (2017) · Open Forum Infectious Diseases

Antifungal resistance and susceptibilityAntibiotic Use and Resistance

Cited by 14

1722. The changing epidemiology of candidemia in the United States: injection drug use as an emerging risk factor for candidemia

Zhang, A. Y., Shrum, S., Williams, S., Vonbank, B., Hillis, S., Barter, D., Petnic, S., Harrison, L. H., Dumyati, G., Phipps, E. C., et al. (2018) · Open Forum Infectious Diseases

Antifungal resistance and susceptibilityInfective Endocarditis Diagnosis and Management

Cited by 2